Results 91 to 100 of about 16,725 (189)

Searching for Selective Cyclin-Dependent Kinase Inhibitors to Target the Retinoblastoma/p16 Cancer Gene Pathway [PDF]

JNCI Journal of the National Cancer Institute, 2001
A. Kubo, F. J. Kaye
openaire   +1 more source

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen

npj Breast Cancer
Aberrant cyclin-dependent kinase 2 (CDK2) activity is implicated as a resistance mechanism to CDK4/6 inhibitors (CDK4/6i) in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer.
Nealia C. House, Maxine M. Chen, Sima Khazaei, Victoria Brown, Philip Ramsden, David H. Peng, Sydney Moore, Liang Yuan, Rentian Wu, Fangyang Wang, Linjie Luo, Ningping Feng, Christopher A. Bristow, Timothy A. Yap, Khandan Keyomarsi, Joseph R. Marszalek, Scott Ribich, Mikael L. Rinne, Lakshmi B. Muthuswamy, Kerrie L. Faia   +19 more
doaj   +1 more source

Arresting idiopathic pulmonary fibrosis progression: EZY-1 targets mTORC2 to inhibit senescence-associated secretory phenotype

Food Science and Human Wellness
EZY-1, a bioactive compound derived from the edible seaweed Eucheuma, was identified as a potent and selective mechanistic target of rapamycin complex 2 (mTORC2) inhibitor.
Mingjin Tu, Huajun Yu, Lili Chen, Xiaoqin Huang, Liuyan He, Rongrong Chen, Xilian Tang, Jun Wu, Haitao Zhang   +8 more
doaj   +1 more source

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers. [PDF]

Front Immunol
Cui J, Zhang Y, Wu Y, Zhang G, Lan J, Wang Y.   +5 more
europepmc   +1 more source

Precision targeting of <i>CCNE1</i>-amplified tumors-lessons from BLU-222 and beyond. [PDF]

Transl Cancer Res
Rantanen F, Ungureanu D.
europepmc   +1 more source

Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies. [PDF]

Oncol Res
Patwekar M, Patwekar F, Kari ZA, Zain MRAM, Mohammed A, Sharma R.   +5 more
europepmc   +1 more source

PRKN Ser131 phosphorylation promotes cigarette smoke-induced mitophagy impairment and epithelial cell senescence via MKK3/p38 MAPK activation: An in vitro and in vivo study. [PDF]

Tob Induc Dis
Hu Y, Liu J, Zhang M, Qu J, Hao W, Zhu X, Wu D, Jiang S, Qu Y.   +8 more
europepmc   +1 more source

p53; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A; ARF) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on <i>KRAS/NF1</i> Mutational Status. [PDF]

Int J Mol Sci
Bittner M, Llaurado Fernandez M, Hoenisch J, Leung YY, Kim H, Wong NKY, Pishas KI, Cheasley D, Cowley KJ, Simpson KJ, Lin YY, Volik S, Le Bihan S, Collins CC, Köbel M, Carey MS.   +15 more
europepmc   +1 more source

p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. [PDF]

Sci Signal
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL.   +7 more
europepmc   +1 more source